Ingenew Pharma has concluded a clinical trial of hesperidin therapy in symptomatic Covid-19 patients who are not vaccinated.
Hesperidin is claimed to possess anti-oxidant as well as anti-inflammatory properties and has the ability to hinder SARS-CoV-2 entry and replication.
The double-blind placebo-controlled trial enrolled 216 subjects, who were randomised to receive either a once-a-day 1000mg dose of hesperidin or placebo for 14 days.
It was carried out and coordinated by the Montreal Health Innovations Coordinating Center in Canada virtually.
This patient-centred method permitted people to take part in clinical trials from the at-home setting, aiding enrolment, retention and follow-up of subjects using digital tools.
In the trial, 13 symptoms were tracked, including fever, shortness of breath, cough and anosmia called Group A symptoms.
At day one, Group A symptoms in hesperidin and the placebo groups were 88.5% and 88.8%, respectively.
On day 14, these symptoms were reduced to 58.5% with hesperidin treatment as against 49.4% for the placebo arm, respectively.
During the same time, 15 participants in the placebo arm and 28 people in the hesperidin arm did not report symptoms, which could be attributable to symptomatic improvement and reduced willingness to participate for those who felt better.
Furthermore, no safety concerns were reported in both the trial arms.
The company noted that if missing results are interpreted to indicate ‘no symptoms’, the hesperidin arm demonstrates a statistically significant decline of 14.5% of Group A symptoms.
Ingenew Pharma president Pierre Laurin said: “This clinical trial was successfully executed under challenging conditions imposed by the pandemic and is an early example illustrating the potential of virtual clinical trials that do not require in-person visits.
“Scientists were able to monitor the effect of a potential treatment for Covid-19 without putting at risk the subjects and the healthcare professionals involved in the study”.